These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 23417217)
1. Market failure in the pharmaceutical industry and how it can be overcome: the CureShare mechanism. Levy M; Rizansky A Eur J Health Econ; 2014 Mar; 15(2):143-56. PubMed ID: 23417217 [TBL] [Abstract][Full Text] [Related]
2. The undiscovered Argentine pharmaceutical market. Felix PF; Thomas RK; Pol LG Mark Health Serv; 2001; 21(4):12-6. PubMed ID: 11763647 [TBL] [Abstract][Full Text] [Related]
3. Global Generic Medicines--Health Network Communications' Second Annual Summit. Burck B IDrugs; 2008 May; 11(5):328-30. PubMed ID: 18465671 [No Abstract] [Full Text] [Related]
4. The effects of rebate contracts on the health care system. Graf J Eur J Health Econ; 2014 Jun; 15(5):477-87. PubMed ID: 23793870 [TBL] [Abstract][Full Text] [Related]
5. Are pharmaceutical marketing decisions calibrated to communications effects? Cavusgil E; Calantone R Health Mark Q; 2011 Oct; 28(4):317-36. PubMed ID: 22054028 [TBL] [Abstract][Full Text] [Related]
6. The pharmaceuticalisation of society? A framework for analysis. Williams SJ; Martin P; Gabe J Sociol Health Illn; 2011 Jul; 33(5):710-25. PubMed ID: 21371048 [TBL] [Abstract][Full Text] [Related]
7. Pharmaceutical marketing in a new age. Effective campaigns still need to focus on what customers want. Rao SK Mark Health Serv; 2002; 22(1):6-12. PubMed ID: 11881547 [TBL] [Abstract][Full Text] [Related]
8. [Drugs in the European Union: the health-market complex]. Antoñanzas F; Rodríguez R; Sacristán JA; Illa R Gac Sanit; 2005; 19(2):151-67. PubMed ID: 15860163 [TBL] [Abstract][Full Text] [Related]
9. When Science is Not Enough: A Framework Towards More Customer-Focused Drug Development. Oraiopoulos N; Dunlop WCN Adv Ther; 2017 Jul; 34(7):1572-1583. PubMed ID: 28625003 [TBL] [Abstract][Full Text] [Related]
10. Globalization in the pharmaceutical industry, Part II. Casadio Tarabusi C; Vickery G Int J Health Serv; 1998; 28(2):281-303. PubMed ID: 9595345 [TBL] [Abstract][Full Text] [Related]
11. [An analysis of the pharmaceuticals market in Vietnam]. Simonet D Sante; 2001; 11(3):155-60. PubMed ID: 11641078 [TBL] [Abstract][Full Text] [Related]
12. Alcohol medications development: advantages and caveats of government/academia collaborating with the pharmaceutical industry. Litten RZ; Ryan M; Falk D; Fertig J Alcohol Clin Exp Res; 2014 May; 38(5):1196-9. PubMed ID: 24689461 [TBL] [Abstract][Full Text] [Related]
13. Prescription drugs and managed care: can 'free-market détente' hold? Moran DW Health Aff (Millwood); 2000; 19(2):63-77. PubMed ID: 10718023 [TBL] [Abstract][Full Text] [Related]
14. Managing the pharmaceutical industry-health system interface. Zarowitz BJ; Muma B; Coggan P; Davis G; Barkley GL Ann Pharmacother; 2001 Dec; 35(12):1661-8. PubMed ID: 11793639 [TBL] [Abstract][Full Text] [Related]
15. The danger of in-kind drug donations to the Global Fund. Baker BK; Ombaka E Lancet; 2009 Apr; 373(9670):1218-21. PubMed ID: 18848353 [No Abstract] [Full Text] [Related]
16. [Adaptation possibility of chosen aspects of pharmaceutical marketing for realization of promotion in health care]. Syrycki M Wiad Lek; 2002; 55 Suppl 1():482-8. PubMed ID: 15002289 [TBL] [Abstract][Full Text] [Related]
17. Marketing to the consumer: perspectives from the pharmaceutical industry. David C Mark Health Serv; 2001; 21(1):5-11. PubMed ID: 11291513 [TBL] [Abstract][Full Text] [Related]
19. One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industry. Billette de Villemeur E; Versaevel B J Health Econ; 2019 May; 65():260-283. PubMed ID: 31158785 [TBL] [Abstract][Full Text] [Related]
20. The next front. Fetter MS Medsurg Nurs; 1998 Aug; 7(4):186-7. PubMed ID: 9782887 [No Abstract] [Full Text] [Related] [Next] [New Search]